» Articles » PMID: 20385270

Radiation Therapy As Part of Local Control of Metastatic Neuroblastoma: the St Jude Children's Research Hospital Experience

Overview
Journal J Pediatr Surg
Date 2010 Apr 14
PMID 20385270
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: The purpose of the study was to compare outcomes of pediatric patients with high-risk metastatic neuroblastoma who received radiotherapy (RT) with those of patients who did not.

Patients And Methods: We reviewed the records of 63 patients with newly diagnosed metastatic neuroblastoma treated at our institution (1989-2001) to investigate their characteristics at presentation, dose and field of RT, treatment response, and failure patterns.

Results: Seventeen patients received RT, and 46 did not. In the RT group, a greater percentage of patients had residual disease before consolidation than did those in the no-RT group (88.2% vs 69.6%, P = .008). Gross total resection was achieved less often in the RT group (65% vs 89%, P = .055), but the 5-year cumulative incidences of local failure were similar (35.3% +/- 12.4% vs 32.6% +/- 7.1%). Although there was no difference in 5-year event-free survival, overall survival was better in the no-RT group (47.8% +/- 7.2% vs 23.5% +/- 9.2%, P = .026).

Conclusion: The addition of RT to the therapy of a group of patients with more residual locoregional disease appeared to improve the local failure rate to approximately that of patients with less residual disease. Radiotherapy may provide even greater benefit to those with less residual disease before consolidation.

Citing Articles

Local MRI before and after Tumor Resection in Neuroblastoma: Impact of Residual Disease on Event Free Survival.

Schafer J, Gassenmaier S, Warmann S, Urla C, Frauenfeld L, Flaadt T J Clin Med. 2023; 12(23).

PMID: 38068349 PMC: 10707530. DOI: 10.3390/jcm12237297.


A Phase II Trial of a Personalized, Dose-Intense Administration Schedule of Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-Risk Neuroblastoma-LuDO-N.

Sundquist F, Georgantzi K, Brunsvig Jarvis K, Brok J, Koskenvuo M, Rascon J Front Pediatr. 2022; 10:836230.

PMID: 35359899 PMC: 8960300. DOI: 10.3389/fped.2022.836230.


Proton Beam Therapy for Children With Neuroblastoma: Experiences From the Prospective KiProReg Registry.

Jazmati D, Butzer S, Hero B, Ahmad Khalil D, Merta J, Baumer C Front Oncol. 2021; 10:617506.

PMID: 33552991 PMC: 7855697. DOI: 10.3389/fonc.2020.617506.


The importance of local control management in high-risk neuroblastoma in South Africa.

Van Heerden J, Kruger M, Esterhuizen T, Hendricks M, Geel J, Buchner A Pediatr Surg Int. 2020; 36(4):457-469.

PMID: 32112128 DOI: 10.1007/s00383-020-04627-x.


Primary thoracic neuroblastoma in an adult: A rare case report.

Tan Y, Li J, Li W, Yang R Medicine (Baltimore). 2019; 98(30):e16564.

PMID: 31348281 PMC: 6709284. DOI: 10.1097/MD.0000000000016564.


References
1.
Dickson P, Hamner J, Sims T, Fraga C, Ng C, Rajasekeran S . Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res. 2007; 13(13):3942-50. DOI: 10.1158/1078-0432.CCR-07-0278. View

2.
McGregor L, Rao B, Davidoff A, Billups C, Hongeng S, Santana V . The impact of early resection of primary neuroblastoma on the survival of children older than 1 year of age with stage 4 disease: the St. Jude Children's Research Hospital Experience. Cancer. 2005; 104(12):2837-46. DOI: 10.1002/cncr.21566. View

3.
Brodeur G, Seeger R, Schwab M, Varmus H, Bishop J . Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 1984; 224(4653):1121-4. DOI: 10.1126/science.6719137. View

4.
De Bernardi B , PIANCA C, Pistamiglio P, Veneselli E, Viscardi E, Pession A . Neuroblastoma with symptomatic spinal cord compression at diagnosis: treatment and results with 76 cases. J Clin Oncol. 2001; 19(1):183-90. DOI: 10.1200/JCO.2001.19.1.183. View

5.
Berthold F, Hero B, Kremens B, Handgretinger R, Henze G, Schilling F . Long-term results and risk profiles of patients in five consecutive trials (1979-1997) with stage 4 neuroblastoma over 1 year of age. Cancer Lett. 2003; 197(1-2):11-7. DOI: 10.1016/s0304-3835(03)00076-4. View